Cash Flow Statement

Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate Effect Exchange Rate Effect Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Ratios

Cyclerion Therapeutics (CYCN) Asset Writedowns and Impairment (2023)

Cyclerion Therapeutics has reported Asset Writedowns and Impairment over the past 1 years, most recently at $3.3 million for Q3 2023.

Quarterly results put Asset Writedowns and Impairment at $3.3 million for Q3 2023, changed N/A from a year ago — trailing twelve months through Dec 2024 was $3.3 million (changed 0.0% YoY), and the annual figure for FY2023 was $3.3 million, changed.
Asset Writedowns and Impairment for Q3 2023 was $3.3 million at Cyclerion Therapeutics.
Over the last five years, Asset Writedowns and Impairment for CYCN hit a ceiling of $3.3 million in Q3 2023 and a floor of $3.3 million in Q3 2023.